RCKT - Rocket Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cranbury,
United States
Type: Equity
RCKT price evolution
RCKT
| (in millions $) | 30 Jun 2023 | 31 Mar 2023 | 31 Jan 2023 | 30 Sep 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $46.98 | $66.38 | $142.47 | $198.48 |
| Short term investments | $261.96 | $266.5 | $215.88 | $109.86 |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $312.07 | $338.03 | $364.06 | $311.13 |
| Long term investments | $28.96 | $43.28 | ||
| Property, plant & equipment | $82.92 | $81.09 | $77.64 | $73.51 |
| Goodwill & intangible assets | $64.88 | $64.88 | $64.88 | $30.82 |
| Total noncurrent assets | $149.71 | $176.72 | $187.75 | $106.13 |
| Total investments | $261.96 | $295.46 | $259.15 | $109.86 |
| Total assets | $461.78 | $514.76 | $551.81 | $417.26 |
| Current liabilities | ||||
| Accounts payable | $31.35 | $28.61 | $36.66 | $27.82 |
| Deferred revenue | ||||
| Short long term debt | $2.99 | $2.6 | $2.51 | $2.36 |
| Total current liabilities | $34.35 | $31.21 | $39.17 | $30.18 |
| Long term debt | $22.39 | $22.8 | $19.27 | $19.73 |
| Total noncurrent liabilities | $24.46 | $24.68 | $22.95 | $19.77 |
| Total debt | $25.39 | $25.4 | $22.87 | $22.09 |
| Total liabilities | $58.81 | $55.88 | $62.12 | $49.95 |
| Shareholders' equity | ||||
| Retained earnings | -$837.81 | -$772.11 | -$713.77 | -$647.05 |
| Other shareholder equity | -$0.72 | -$0.09 | -$0.36 | -$0.6 |
| Total shareholder equity | $402.97 | $458.88 | $489.69 | $367.31 |
| (in millions $) | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $142.47 | $234.49 | $299.12 | $187.36 |
| Short term investments | $215.88 | $156.05 | $185.62 | $118.73 |
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $364.06 | $392.06 | $487.35 | $307.75 |
| Long term investments | $43.28 | |||
| Property, plant & equipment | $77.64 | $72.35 | $70.64 | $31.35 |
| Goodwill & intangible assets | $64.88 | $30.82 | $30.82 | $31.04 |
| Total noncurrent assets | $187.75 | $104.96 | $103.48 | $64.37 |
| Total investments | $259.15 | $156.05 | $185.62 | $118.73 |
| Total assets | $551.81 | $497.02 | $590.82 | $372.12 |
| Current liabilities | ||||
| Accounts payable | $36.66 | $19.61 | $25.47 | $17.35 |
| Deferred revenue | ||||
| Short long term debt | $2.51 | $2.55 | $7.14 | $0.96 |
| Total current liabilities | $39.17 | $22.17 | $32.62 | $18.31 |
| Long term debt | $19.27 | $20.05 | $54.55 | $46.49 |
| Total noncurrent liabilities | $22.95 | $20.13 | $54.69 | $46.52 |
| Total debt | $22.87 | $22.6 | $61.7 | $47.45 |
| Total liabilities | $62.12 | $42.3 | $87.31 | $64.82 |
| Shareholders' equity | ||||
| Retained earnings | -$713.77 | -$491.91 | -$322.84 | -$183.14 |
| Other shareholder equity | -$0.36 | -$0.16 | -$0.04 | $0.02 |
| Total shareholder equity | $489.69 | $454.72 | $503.52 | $307.3 |
| (in millions $) | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $51.38 | $46.37 | $50.04 | $43.38 |
| Selling, general & administrative | $17.37 | $15.82 | $19.05 | $15.11 |
| Total operating expenses | $68.76 | $62.19 | $69.08 | $58.49 |
| Operating income | -$68.76 | -$62.19 | -$69.08 | -$58.49 |
| Income from continuing operations | ||||
| EBIT | -$65.23 | -$57.87 | -$66.26 | -$57.29 |
| Income tax expense | ||||
| Interest expense | $0.47 | $0.47 | $0.47 | $0.47 |
| Net income | ||||
| Net income | -$65.7 | -$58.34 | -$66.72 | -$57.76 |
| Income (for common shares) | -$65.7 | -$58.34 | -$66.72 | -$57.76 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $165.57 | $125.48 | $106.38 | $58.62 |
| Selling, general & administrative | $58.77 | $41.77 | $27.92 | $17.53 |
| Total operating expenses | $224.34 | $167.25 | $134.3 | $76.15 |
| Operating income | -$224.34 | -$167.25 | -$134.3 | -$76.15 |
| Income from continuing operations | ||||
| EBIT | -$220 | -$166.09 | -$132.73 | -$71.31 |
| Income tax expense | ||||
| Interest expense | $1.86 | $2.98 | $6.97 | $5.96 |
| Net income | ||||
| Net income | -$221.86 | -$169.07 | -$139.7 | -$77.27 |
| Income (for common shares) | -$221.86 | -$169.07 | -$139.7 | -$77.27 |
| (in millions $) | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 | 30 Sep 2022 |
|---|---|---|---|---|
| Net income | -$65.7 | -$58.34 | -$66.72 | -$57.76 |
| Operating activities | ||||
| Depreciation | $1.73 | $1.67 | $3.38 | $1.08 |
| Business acquisitions & disposals | $42.73 | |||
| Stock-based compensation | $10.24 | $8.91 | $9.69 | $7.68 |
| Total cash flows from operations | -$50.87 | -$57.56 | -$56.02 | -$43.86 |
| Investing activities | ||||
| Capital expenditures | -$4.15 | -$3.02 | -$3.26 | -$0.5 |
| Investments | $35.35 | -$33.7 | -$148.05 | $23.97 |
| Total cash flows from investing | $31.21 | -$36.72 | -$108.58 | $23.46 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.18 | $18.34 | $108.44 | $29.53 |
| Net borrowings | ||||
| Total cash flows from financing | $0.18 | $18.34 | $108.44 | $29.53 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$19.48 | -$75.94 | -$56.17 | $9.13 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Net income | -$221.86 | -$169.07 | -$139.7 | -$77.27 |
| Operating activities | ||||
| Depreciation | $6.27 | $5.37 | $1.15 | $0.43 |
| Business acquisitions & disposals | $42.73 | |||
| Stock-based compensation | $31.01 | $29.24 | $18.57 | $13.37 |
| Total cash flows from operations | -$178.14 | -$121.16 | -$74.64 | -$64.66 |
| Investing activities | ||||
| Capital expenditures | -$8.62 | -$7.71 | -$29.06 | -$23.27 |
| Investments | -$103.43 | $26.57 | -$67.53 | -$15.74 |
| Total cash flows from investing | -$69.33 | $18.85 | -$96.59 | -$39.01 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $155.29 | $37.68 | $283.84 | $178.13 |
| Net borrowings | -$0.24 | |||
| Total cash flows from financing | $155.29 | $37.68 | $282.99 | $177.79 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$92.18 | -$64.63 | $111.76 | $74.12 |
News
Fundamentals
| Market cap | $1.65B |
|---|---|
| Enterprise value | $1.63B |
| Shares outstanding | 80.52M |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$238.78M |
| EBIT | -$246.65M |
| Net Income | -$248.51M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -6.64 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | -6.82 |
| EV/EBIT | -6.60 |
| P/S ratio | N/A |
| P/B ratio | 4.09 |
| Book/Share | 5.01 |
| Cash/Share | 0.58 |
| EPS | -$3.09 |
|---|---|
| ROA | -51.09% |
| ROE | -57.83% |
| Debt/Equity | 0.13 |
|---|---|
| Net debt/EBITDA | -0.05 |
| Current ratio | 9.09 |
| Quick ratio | 9.09 |